Easton Pharmaceuticals, Inc. (EAPH)

[likwit]

https://seekingalpha.com/article/2303495-reevaluating-the-schwag-easton-pharmaceuticals-still-schwag

Reevaluating The Schwag: Easton Pharmaceuticals, Still Schwag

Summary

EAPH continues reports that it "has not generated material revenues from the sale of products".

With limited cash, the company has threatened to file a lawsuit against a "certain Seeking Alpha writer," most likely using the paid-in capital from this past year.

...

Revisiting Easton Pharmaceuticals

During the peak of the marijuana stock bull market this year, I published an article entitled "Marijuana Stocks: Investing in Canadian Schwag" that discussed three companies that I felt were using the momentum of the pot stock frenzy to boost share price. The term "Schwag" was to denote a company of the low quality, as in the slang term for the lowest grade of marijuana. A company that stood out was Easton Pharmaceuticals (OTCPK:EAPH).

Prior to this, I have publicly expressed fascination with companies attempting to enter the Canadian medical marijuana space. The company that caught my eye as a potential player was EAPH. After looking over the filings, I discovered several red flags that can be seen even in its most up-to-date filing. To quote:

"There have been no revenues related to the L.A.M. IPMTM based products to date."
"To date EASTON PHARMACEUTICALS has not generated material revenues from the sale of products and expects to incur losses until sufficient revenues are earned from the sale of its first product to operate on a net profit basis."